Online inquiry

IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ113MR)

This product GTTS-WQ113MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ113MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9617MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ4408MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ9632MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ7197MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ14307MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ5531MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ13081MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ10813MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M7824
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW